Using log rank test and Kaplan-Meier survival analysis, we showed tumors with high level NFATc2 expression had significantly shorter recurrence-free survival (RFS) and cancer-specific overall survival (OS) (Figure 1E,F). This evidence concerns the gene NFATC2 and cancer.